CO-TENIDONE BP

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

ATENOLOL CHLORTALIDONE

Available from:

Norton Waterford

Dosage:

50/12.5 Milligram

Pharmaceutical form:

Tablets

Authorization date:

1996-10-10

Summary of Product characteristics

PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Co-Tenidone Tablets BP 50/12.5mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Atenolol 50mg and Chlorthalidone 12.5mg.
3 PHARMACEUTICAL FORM
Circular, white film coated tablets embossed 'Co-Ten 50' on
one side, plain on the reverse.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
The management of hypertension.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
_Adults:_
One tablet daily.
Older patients with hypertension who do not respond to
low dose therapy with a single agent should
have a satisfactory 
response to a single tablet daily
of Co-Tenidone 50/12.5mg. Where hypertensive control is not achieved,
addition of a 
small dose of a third agent e.g. a vasodilator may
be appropriate. 
_Elderly:_
Dosage requirements are often lower in
this age group. Older patients with hypertension who do
not respond to low 
dose therapy with a single agent should have a satisfactory
response to a single tablet daily of Co-Tenidone 50/12.5mg.
Where hypertensive control is not achieved, addition
of a small dose of a third agent, e.g. a vasodilator may be 
appropriate.
_Children:_
There is no paediatric experience of this drug and
it is therefore not recommended for use in children.
_Renal Failure:_
In patients with severe renal impairment a reduction in daily
dosage or in frequency of administration may be 
necessary.
4.3 CONTRAINDICATIONS
1.
2
nd
 or 3
rd
 degree atrioventricular block
2.
Severe bradycardia
3.
Uncontrolled or digitalis/diuretic refractory heart failure
4.
Cardiogenic shock
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 16/03/2006_
_CRN 2021092_
_page number: 1_
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE
_Cardiac_
Special care shoul